<p>根据公司在最近向美国证券交易委员会提交的 13F 文件，Strategies Wealth Advisors LLC 在第一季度将其在礼来公司的持股增加了 41.2%。该基金在本季度购买了 1,049 股后，持有该公司 3,595 股股票。到最近一个季度末，Strategies Wealth Advisors LLC 在礼来公司的持股价值为 2,969,000 美元。</p>
<ul>
<li>Ozempic 热潮：Hims 和礼来引领医疗投资</li>
</ul>
<p>其他大型投资者最近也对该公司的持仓进行了调整。Knightsbridge Asset Management LLC 在第四季度将其在礼来公司的股份增加了 1.9%。Knightsbridge Asset Management LLC 目前持有 813 股该公司的股票，价值 628,000 美元，此前在该期间购买了 15 股。Corient IA LLC 在第一季度购买了价值 570,000 美元的礼来公司新股份。LS Investment Advisors LLC 在第一季度将其在礼来公司的股份增加了 1.7%。LS Investment Advisors LLC 目前持有 2,340 股该公司的股票，价值 1,933,000 美元，此前在该期间购买了 40 股。Prism Advisors Inc.在第一季度购买了价值 207,000 美元的礼来公司新股份。最后，Hemington Wealth Management 在第一季度将其在礼来公司的股份增加了 14.4%。Hemington Wealth Management 目前持有 985 股该公司的股票，价值 813,000 美元，此前在该期间购买了 124 股。当前 82.53% 的股票由机构投资者持有。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，首席执行官 David A. Ricks 在 8 月 12 日星期二收购了 1,632 股礼来公司的股票。每股的平均购买价格为 644.77 美元，总交易额为 1,052,264.64 美元。收购后，首席执行官直接持有 546,601 股该公司的股票，价值 352,431,926.77 美元。这笔交易代表了其持仓的 0.30% 的增加。该购买在向美国证券交易委员会的法律文件中披露，具体信息可在此链接中找到。此外，董事 J Erik Fyrwald 在 8 月 12 日星期二的交易中购买了 1,565 股该公司的股票。每股的平均价格为 642.33 美元，总交易额为 1,005,246.45 美元。完成购买后，该董事在公司中持有 74,578 股，价值 47,903,686.74 美元。这笔交易使其持股增加了 2.14%。该购买的披露信息可以在这里找到。在过去三个月中，内部人士购买了价值 2,894,841 美元的 4,514 股公司股票。目前 0.13% 的股票由公司内部人士持有。</p>
<h2>礼来公司股票表现</h2>
<ul>
<li>特朗普 GLP-1 试点计划可能推动诺和诺德和礼来</li>
</ul>
<p>礼来公司的股票在周五开盘价为 708.8230 美元。该公司的速动比率为 1.00，流动比率为 1.28，债务与股本比率为 1.86。该公司的 50 日简单移动平均为 756.85 美元，200 日简单移动平均为 791.70 美元。该股票的市值为 6708.7 亿美元，市盈率为 46.33，PEG 比率为 0.98，贝塔值为 0.44。礼来公司的 52 周低点为 623.78 美元，52 周高点为 972.53 美元。</p>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近一次发布财报是在 8 月 7 日星期四。该公司报告本季度每股收益（EPS）为 6.31 美元，超出市场共识预期的 5.59 美元，超出 0.72 美元。该公司本季度的收入为 155.6 亿美元，而分析师预期为 144.0 亿美元。礼来公司的股本回报率为 92.72%，净利润率为 25.91%。该公司的收入同比增长 37.6%。去年同期，该公司每股收益为 3.92 美元。礼来公司已将其 2025 财年的指导目标设定为 21.750-23.000 EPS。分析师平均预计礼来公司本年度将发布 23.48 EPS。</p>
<h2>礼来公司宣布分红</h2>
<ul>
<li>礼来的 14% 财报后下滑是否是买入机会？</li>
</ul>
<p>该公司最近还披露了季度分红，将于 9 月 10 日星期三支付。8 月 15 日星期五的股东将获得 1.50 美元的分红。这代表着每年 6.00 美元的分红和 0.8% 的分红收益率。该分红的除息日为 8 月 15 日星期五。礼来公司的分红支付比率（DPR）目前为 39.22%。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票研究分析师对 LLY 股票发表了评论。富国银行在 5 月 1 日星期四的报告中重申了对礼来公司股票的 “增持” 评级。Wall Street Zen 在 7 月 26 日星期六的研究报告中将礼来公司的评级从 “持有” 上调至 “买入”。Cantor Fitzgerald 在 8 月 13 日星期三的研究报告中将礼来公司的目标价从 975.00 美元下调至 825.00 美元，并对该公司设定了 “增持” 评级。德意志银行在 8 月 11 日星期一的研究报告中将礼来公司的目标价从 1,010.00 美元下调至 900.00 美元，并对该公司设定了 “买入” 评级。最后，Guggenheim 在 8 月 13 日星期三的研究报告中将礼来公司的目标价从 942.00 美元下调至 875.00 美元，并对该公司设定了 “买入” 评级。一位研究分析师对该股票给予了强烈买入评级，十四位给予了买入评级，七位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，礼来公司的共识评级为 “适度买入”，平均目标价为 950.17 美元。</p>
<p><strong>阅读我们关于礼来公司的最新研究报告</strong></p>
<h2>关于礼来公司</h2>
<p>（免费报告）</p>
<p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供用于糖尿病的 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500；用于 2 型糖尿病的 Jardiance、Mounjaro 和 Trulicity；以及用于肥胖症的 Zepbound。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>投资者如何找到最佳的便宜股息股票</li>
<li>身份安全能否推动 CrowdStrike 的下一个增长阶段？</li>
<li>股票拆分意味着什么？</li>
<li>博通被纳入苹果 1000 亿美元的美国投资计划</li>
<li>上海证券交易所综合指数是什么？</li>
<li>Salesforce 现在是个便宜货的三个理由</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在礼来公司吗？</h2>
<p>在你考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>Strategies Wealth Advisors LLC 在第一季度将其在礼来公司的股份增加了 41.2%，额外购买了 1,049 股，总持股量达到 3,595 股，价值 297 万美元。其他投资者也调整了他们的持仓，机构投资者持有该股票的比例为 82.53%。首席执行官 David A. Ricks 和董事 J Erik Fyrwald 最近进行了大量股票购买。礼来公司报告了强劲的第二季度收益，超出预期，并宣布每季度派发 1.50 美元的股息，将于 9 月 10 日支付</p>

<p>Strategies Wealth Advisors LLC raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 41.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,595 shares of the company's stock after buying an additional 1,049 shares during the quarter. Strategies Wealth Advisors LLC's holdings in Eli Lilly and Company were worth $2,969,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据公司在最近向美国证券交易委员会提交的 13F 文件，Strategies Wealth Advisors LLC 在第一季度将其在礼来公司的持股增加了 41.2%。该基金在本季度购买了 1,049 股后，持有该公司 3,595 股股票。到最近一个季度末，Strategies Wealth Advisors LLC 在礼来公司的持股价值为 2,969,000 美元。</p>
</div><ul>
<li>Ozempic Boom: Hims &amp; Eli Lilly Lead Healthcare Bets</li>
</ul>
<div class="lb-trans"><ul>
<li>Ozempic 热潮：Hims 和礼来引领医疗投资</li>
</ul>
</div><p>Other large investors have also recently made changes to their positions in the company. Knightsbridge Asset Management LLC grew its stake in Eli Lilly and Company by 1.9% in the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock worth $628,000 after purchasing an additional 15 shares during the period. Corient IA LLC purchased a new stake in Eli Lilly and Company in the first quarter worth $570,000. LS Investment Advisors LLC grew its stake in Eli Lilly and Company by 1.7% in the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after purchasing an additional 40 shares during the period. Prism Advisors Inc. purchased a new stake in Eli Lilly and Company in the first quarter worth $207,000. Finally, Hemington Wealth Management grew its stake in Eli Lilly and Company by 14.4% in the first quarter. Hemington Wealth Management now owns 985 shares of the company's stock worth $813,000 after purchasing an additional 124 shares during the period. 82.53% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投资者最近也对该公司的持仓进行了调整。Knightsbridge Asset Management LLC 在第四季度将其在礼来公司的股份增加了 1.9%。Knightsbridge Asset Management LLC 目前持有 813 股该公司的股票，价值 628,000 美元，此前在该期间购买了 15 股。Corient IA LLC 在第一季度购买了价值 570,000 美元的礼来公司新股份。LS Investment Advisors LLC 在第一季度将其在礼来公司的股份增加了 1.7%。LS Investment Advisors LLC 目前持有 2,340 股该公司的股票，价值 1,933,000 美元，此前在该期间购买了 40 股。Prism Advisors Inc.在第一季度购买了价值 207,000 美元的礼来公司新股份。最后，Hemington Wealth Management 在第一季度将其在礼来公司的股份增加了 14.4%。Hemington Wealth Management 目前持有 985 股该公司的股票，价值 813,000 美元，此前在该期间购买了 124 股。当前 82.53% 的股票由机构投资者持有。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares of the company's stock, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director J Erik Fyrwald bought 1,565 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 David A. Ricks 在 8 月 12 日星期二收购了 1,632 股礼来公司的股票。每股的平均购买价格为 644.77 美元，总交易额为 1,052,264.64 美元。收购后，首席执行官直接持有 546,601 股该公司的股票，价值 352,431,926.77 美元。这笔交易代表了其持仓的 0.30% 的增加。该购买在向美国证券交易委员会的法律文件中披露，具体信息可在此链接中找到。此外，董事 J Erik Fyrwald 在 8 月 12 日星期二的交易中购买了 1,565 股该公司的股票。每股的平均价格为 642.33 美元，总交易额为 1,005,246.45 美元。完成购买后，该董事在公司中持有 74,578 股，价值 47,903,686.74 美元。这笔交易使其持股增加了 2.14%。该购买的披露信息可以在这里找到。在过去三个月中，内部人士购买了价值 2,894,841 美元的 4,514 股公司股票。目前 0.13% 的股票由公司内部人士持有。</p>
</div><h2>Eli Lilly and Company Stock Performance</h2>
<div class="lb-trans"><h2>礼来公司股票表现</h2>
</div><ul>
<li>Trump GLP-1 Pilot Program Could Boost Novo Nordisk &amp; Eli Lilly</li>
</ul>
<div class="lb-trans"><ul>
<li>特朗普 GLP-1 试点计划可能推动诺和诺德和礼来</li>
</ul>
</div><p>Shares of LLY opened at $708.8230 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The business has a 50-day simple moving average of $756.85 and a two-hundred day simple moving average of $791.70. The stock has a market cap of $670.87 billion, a price-to-earnings ratio of 46.33, a PEG ratio of 0.98 and a beta of 0.44. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $972.53.</p>
<div class="lb-trans"><p>礼来公司的股票在周五开盘价为 708.8230 美元。该公司的速动比率为 1.00，流动比率为 1.28，债务与股本比率为 1.86。该公司的 50 日简单移动平均为 756.85 美元，200 日简单移动平均为 791.70 美元。该股票的市值为 6708.7 亿美元，市盈率为 46.33，PEG 比率为 0.98，贝塔值为 0.44。礼来公司的 52 周低点为 623.78 美元，52 周高点为 972.53 美元。</p>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm's revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近一次发布财报是在 8 月 7 日星期四。该公司报告本季度每股收益（EPS）为 6.31 美元，超出市场共识预期的 5.59 美元，超出 0.72 美元。该公司本季度的收入为 155.6 亿美元，而分析师预期为 144.0 亿美元。礼来公司的股本回报率为 92.72%，净利润率为 25.91%。该公司的收入同比增长 37.6%。去年同期，该公司每股收益为 3.92 美元。礼来公司已将其 2025 财年的指导目标设定为 21.750-23.000 EPS。分析师平均预计礼来公司本年度将发布 23.48 EPS。</p>
</div><h2>Eli Lilly and Company Announces Dividend</h2>
<div class="lb-trans"><h2>礼来公司宣布分红</h2>
</div><ul>
<li>Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?</li>
</ul>
<div class="lb-trans"><ul>
<li>礼来的 14% 财报后下滑是否是买入机会？</li>
</ul>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 39.22%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，将于 9 月 10 日星期三支付。8 月 15 日星期五的股东将获得 1.50 美元的分红。这代表着每年 6.00 美元的分红和 0.8% 的分红收益率。该分红的除息日为 8 月 15 日星期五。礼来公司的分红支付比率（DPR）目前为 39.22%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities research analysts have commented on LLY shares. Wells Fargo &amp; Company reissued an &#34;overweight&#34; rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Wall Street Zen upgraded Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, July 26th. Cantor Fitzgerald decreased their price target on Eli Lilly and Company from $975.00 to $825.00 and set an &#34;overweight&#34; rating for the company in a research note on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft decreased their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a &#34;buy&#34; rating for the company in a research note on Monday, August 11th. Finally, Guggenheim decreased their price target on Eli Lilly and Company from $942.00 to $875.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $950.17.</p>
<div class="lb-trans"><p>几位股票研究分析师对 LLY 股票发表了评论。富国银行在 5 月 1 日星期四的报告中重申了对礼来公司股票的 “增持” 评级。Wall Street Zen 在 7 月 26 日星期六的研究报告中将礼来公司的评级从 “持有” 上调至 “买入”。Cantor Fitzgerald 在 8 月 13 日星期三的研究报告中将礼来公司的目标价从 975.00 美元下调至 825.00 美元，并对该公司设定了 “增持” 评级。德意志银行在 8 月 11 日星期一的研究报告中将礼来公司的目标价从 1,010.00 美元下调至 900.00 美元，并对该公司设定了 “买入” 评级。最后，Guggenheim 在 8 月 13 日星期三的研究报告中将礼来公司的目标价从 942.00 美元下调至 875.00 美元，并对该公司设定了 “买入” 评级。一位研究分析师对该股票给予了强烈买入评级，十四位给予了买入评级，七位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，礼来公司的共识评级为 “适度买入”，平均目标价为 950.17 美元。</p>
</div><p><strong>Read Our Latest Research Report on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于礼来公司的最新研究报告</strong></p>
</div><h2>About Eli Lilly and Company</h2>
<div class="lb-trans"><h2>关于礼来公司</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供用于糖尿病的 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500；用于 2 型糖尿病的 Jardiance、Mounjaro 和 Trulicity；以及用于肥胖症的 Zepbound。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>How Investors Can Find the Best Cheap Dividend Stocks</li>
<li>Can Identity Security Fuel CrowdStrike’s Next Growth Phase?</li>
<li>What Does a Stock Split Mean?</li>
<li>Broadcom Named in Apple’s $100B U.S. Investment Plan</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>3 Reasons Salesforce Is a Bargain Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>投资者如何找到最佳的便宜股息股票</li>
<li>身份安全能否推动 CrowdStrike 的下一个增长阶段？</li>
<li>股票拆分意味着什么？</li>
<li>博通被纳入苹果 1000 亿美元的美国投资计划</li>
<li>上海证券交易所综合指数是什么？</li>
<li>Salesforce 现在是个便宜货的三个理由</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Strategies Wealth Advisors LLC 购买了礼来公司 1,049 股股票